Aethlon Medical Advances Hemopurifier for Oncology and Extracellular Vesicle Modulation

Aethlon accelerates Hemopurifier development in oncology and extracellular vesicle science

Hemopurifier advances in Australian oncology study and EV modulation

Aethlon Medical is advancing clinical deployment of its Hemopurifier as enrollment and treatment in Cohort 2 of an Australian oncology trial are actively underway. The nine‑to‑18 patient study evaluates the safety and feasibility of Hemopurifier treatments and seeks to determine dosing in patients with solid tumors whose disease is stable or progressing while they receive anti‑PD‑1 therapies Keytruda or Opdivo. Company officials frame the trial as an early test of whether extracorporeal removal of pathogenic particles can augment or restore anti‑PD‑1 activity in difficult‑to‑treat solid tumors.

Data from Cohort 1 provide early biological signals that the approach is tolerable and may affect tumor‑related biology. Aethlon reports favorable directional improvements in extracellular vesicle (EV) levels and immune cell numbers alongside safety and tolerability observations, findings the company interprets as supportive of continued clinical exploration. Management describes the Hemopurifier as a "pipeline within a single device," emphasizing its potential for multi‑indication therapeutic application rather than as a single‑use technology.

Parallel preclinical work focuses on EVs and immune dysregulation, broadening the device’s translational rationale. Aethlon highlights Long COVID data posted on bioRxiv and submitted for peer review showing that the Hemopurifier’s GNA affinity resin binds EVs from Long COVID samples and reduces microRNAs associated with immune dysregulation. The company says it is exploring additional EV cargo removal by the Hemopurifier and aims to translate those preclinical signals into measurable clinical benefit in infectious and oncology settings.

Operational, regulatory and partnership activity

Aethlon stresses operational discipline as it advances clinical programs, reporting year‑to‑date cost efficiencies that lower operating expenses versus the prior year. The company also confirms continued compliance with Nasdaq listing requirements and says all prior compliance matters remain resolved; management schedules a conference call at 4:30 p.m. ET on the day of the release to discuss results and next steps.

Device compatibility work to broaden access

Under a Material Transfer Agreement, partner Stavro is evaluating Hemopurifier compatibility with the SLAMB simplified blood treatment system to enable use in oncology units and infusion centers without large dialysis catheters, dialysis machines or supervising nephrologists. Aethlon emphasizes ongoing technology development to assess Hemopurifier compatibility with simplified blood treatment platforms as part of its strategy to broaden clinical access.